- Home
- IMNM vs RLAY Comparison
IMNM vs RLAY Comparison
Compare IMNM & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- RLAY
- Stock Information
- Founded
- IMNM 2006
- RLAY 2015
- Country
- IMNM United States
- RLAY United States
- Employees
- IMNM N/A
- RLAY N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMNM Health Care
- RLAY Health Care
- Exchange
- IMNM Nasdaq
- RLAY Nasdaq
- Market Cap
- IMNM 1.2B
- RLAY 1.0B
- IPO Year
- IMNM 2020
- RLAY 2020
- Fundamental
- Price
- IMNM $18.12
- RLAY $6.70
- Analyst Decision
- IMNM Strong Buy
- RLAY Strong Buy
- Analyst Count
- IMNM 8
- RLAY 9
- Target Price
- IMNM $25.75
- RLAY $16.00
- AVG Volume (30 Days)
- IMNM 1.4M
- RLAY 2.3M
- Earning Date
- IMNM 11-06-2025
- RLAY 11-06-2025
- Dividend Yield
- IMNM N/A
- RLAY N/A
- EPS Growth
- IMNM N/A
- RLAY N/A
- EPS
- IMNM N/A
- RLAY N/A
- Revenue
- IMNM $9,679,000.00
- RLAY $8,355,000.00
- Revenue This Year
- IMNM N/A
- RLAY $27.30
- Revenue Next Year
- IMNM $85.36
- RLAY $7.43
- P/E Ratio
- IMNM N/A
- RLAY N/A
- Revenue Growth
- IMNM N/A
- RLAY N/A
- 52 Week Low
- IMNM $5.15
- RLAY $1.78
- 52 Week High
- IMNM $18.79
- RLAY $7.64
- Technical
- Relative Strength Index (RSI)
- IMNM 64.32
- RLAY 55.30
- Support Level
- IMNM $16.11
- RLAY $6.04
- Resistance Level
- IMNM $17.94
- RLAY $7.42
- Average True Range (ATR)
- IMNM 1.26
- RLAY 0.42
- MACD
- IMNM 0.02
- RLAY -0.12
- Stochastic Oscillator
- IMNM 86.56
- RLAY 44.08
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).